: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Leukemia

Free Subscription

Articles published in Br J Haematol
Retrieve available abstracts of 513 articles:
HTML format

Single Articles

May 2024

BALDUZZI A
The CAR T-cell race: The rules of the game.
Br J Haematol. 2024;204:1579-1581.
PubMed Abstract available

ZHANG X, Tao C, Long F
Haematoidin in chronic myelomonocytic leukaemia during irregular treatment with hydroxycarbamide.
Br J Haematol. 2024;204:1569-1570.
PubMed

MISHRA AK, Burridge S, Espuelas MO, O'Reilly M, et al
Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1687-1696.
PubMed Abstract available

KRIEGER E, Qayyum R, Toor A
Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.
Br J Haematol. 2024;204:1935-1943.
PubMed Abstract available

LEBECQUE B, Besombes J, Dannus LT, De Antonio M, et al
Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
Br J Haematol. 2024;204:1872-1881.
PubMed Abstract available

JO T, Ueda T, Akahoshi Y, Kondo T, et al
First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1913-1919.
PubMed Abstract available

BOUKOUACI W, Rivera-Franco MM, Volt F, Lajnef M, et al
HLA peptide-binding pocket diversity modulates immunological complications after cord blood transplant in acute leukaemia.
Br J Haematol. 2024;204:1920-1934.
PubMed Abstract available

BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al
The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
Br J Haematol. 2024;204:1649-1659.
PubMed Abstract available

LOH Z, Ashby M, Van Veldhuizen E, Li W, et al
Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
Br J Haematol. 2024;204:1732-1739.
PubMed Abstract available

April 2024

LIU HC, Huang YJ, Jaing TH, Wu KH, et al
Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1(plus) and Day 15 MRD positivity.
Br J Haematol. 2024;204:1344-1353.
PubMed Abstract available

BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1367-1374.
PubMed Abstract available

CHEN X, Li J, Yu L, Hu W, et al
High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
Br J Haematol. 2024;204:1354-1366.
PubMed Abstract available

MOSQUERA ORGUEIRA A, Perez Encinas MM, Diaz Varela N, Wang YH, et al
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
Br J Haematol. 2024;204:1529-1535.
PubMed Abstract available

STENTOFT J
The Mozart effect in chronic myeloid leukaemia.
Br J Haematol. 2024;204:1139-1140.
PubMed Abstract available

PATEL SA
The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
Br J Haematol. 2024;204:1137-1138.
PubMed Abstract available

ZHANG T, Zhang Y, Zhou M, Zhang Z, et al
Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2024;204:1402-1413.
PubMed Abstract available

ALCAZER V, Morisset S, Rea D, Legros L, et al
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
Br J Haematol. 2024;204:1536-1539.
PubMed

JOHNSON IM, Karrar O, Rana M, Iftikhar M, et al
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
Br J Haematol. 2024;204:1232-1237.
PubMed Abstract available

NACHMIAS B, Aumann S, Haran A, Schimmer AD, et al
Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
Br J Haematol. 2024;204:1146-1158.
PubMed Abstract available

ZUCENKA A, Griskevicius L
Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
Br J Haematol. 2024;204:1227-1231.
PubMed Abstract available

SUWANNAYING K, Ong AA, Dhaduk R, Pei D, et al
Quantitative computed tomography analysis of body composition changes in paediatric patients with acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1335-1343.
PubMed Abstract available

FIEDLER W
Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy.
Br J Haematol. 2024;204:1135-1136.
PubMed Abstract available

LIANG P, Xie Y, Liu Z, Wang D, et al
Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
Br J Haematol. 2024;204:1219-1226.
PubMed Abstract available

ROY MOULIK N, Keerthivasagam S, Pandey A, Agiwale J, et al
Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
Br J Haematol. 2024;204:1249-1261.
PubMed Abstract available

MADERO-MARROQUIN R, DuVall AS, Saygin C, Wang P, et al
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
Br J Haematol. 2024;204:1238-1242.
PubMed Abstract available

LIGIA S, Passucci M, Assanto GM, D'Elia GM, et al
Early clearance of hairy cell leukaemia in the bone marrow after first-line treatment with cladribine predicts a favourable outcome.
Br J Haematol. 2024;204:1288-1292.
PubMed Abstract available

March 2024

LARIBI K, Poulain S, Willems L, Merabet F, et al
Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
Br J Haematol. 2024 Mar 19. doi: 10.1111/bjh.19409.
PubMed Abstract available

NG HL, Robinson ME, May PC, Innes AJ, et al
Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
Br J Haematol. 2024;204:945-958.
PubMed Abstract available

SUN H, Zhu Y, Li J, Zhao L, et al
CSF3R P733T is a deleterious germline variant in acute leukaemia showing gain-of-function-like T618I mutation.
Br J Haematol. 2024;204:e31-e33.
PubMed

SHIMONY S, Chen EC
Tri-ing to decipher trisomy AML.
Br J Haematol. 2024;204:751-752.
PubMed Abstract available

TAN JY, Yeo YH, Tan MC, Chavez JC, et al
Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy.
Br J Haematol. 2024;204:1114-1117.
PubMed

ZHAO HG
Should oligomonocytic CMML be classified as an independent disease entity?
Br J Haematol. 2024;204:749-750.
PubMed Abstract available

LAM SSY, Tsui SP, Fung CY, Saw NY, et al
Distinct karyotypic and mutational landscape in trisomy AML.
Br J Haematol. 2024;204:939-944.
PubMed Abstract available

COPLAND M, Ariti C, Thomas IF, Upton L, et al
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
Br J Haematol. 2024;204:871-876.
PubMed Abstract available

CASTANO-DIEZ S, Pomares H, Esteban D, Guijarro F, et al
Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
Br J Haematol. 2024;204:892-897.
PubMed Abstract available

LU Q, Qu W, Wen Y, Ke P, et al
Single-cell RNA-seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML.
Br J Haematol. 2024;204:1100-1104.
PubMed

RAVANDI F, Dohner H, Wei AH, Montesinos P, et al
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Br J Haematol. 2024;204:877-886.
PubMed Abstract available

MONTALBAN-BRAVO G, Jabbour E, Borthakur G, Kadia T, et al
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol. 2024;204:898-909.
PubMed Abstract available

CHEN N, Pan J, Zhou Y, Mao L, et al
Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Br J Haematol. 2024;204:861-870.
PubMed Abstract available

February 2024

COSTA A, Breccia M
How to improve treatment-free remission eligibility in chronic myeloid leukaemia?
Br J Haematol. 2024;204:434-448.
PubMed Abstract available

PARDANANI A, Reichard K, Tefferi A
Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
Br J Haematol. 2024;204:402-414.
PubMed Abstract available

FUJI S, Yuda S, Tada Y, Kano M, et al
A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post-transplant clinical outcome in patients with aggressive ATL.
Br J Haematol. 2024;204:e25-e27.
PubMed

WANG Z, Fan Z, Wu Z, Xuan L, et al
PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2024;204:628-637.
PubMed Abstract available

KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
Br J Haematol. 2024;204:561-565.
PubMed Abstract available

NYQUIST OE, Dalgaard J, Spetalen S, Torkildsen S, et al
Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML.
Br J Haematol. 2024;204:724-729.
PubMed

NARDOZZA AM, Guarnera L, Travaglini S, Ottone T, et al
Characterization of a novel IDH2-R159H mutation in acute myeloid leukaemia: Effects on cell metabolism and differentiation.
Br J Haematol. 2024;204:719-723.
PubMed

RAMAMOORTHY S, Lebrecht D, Schanze D, Schanze I, et al
Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
Br J Haematol. 2024;204:595-605.
PubMed Abstract available

MARK C, Meshinchi S, Joyce B, Gibson B, et al
Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias.
Br J Haematol. 2024;204:576-584.
PubMed Abstract available

SHEN Y, Freeman JA, Kerridge I, Downe P, et al
Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL.
Br J Haematol. 2024;204:487-491.
PubMed Abstract available

BAI L, Zhang ZX, Hu GH, Cheng YF, et al
Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre.
Br J Haematol. 2024;204:585-594.
PubMed Abstract available

January 2024

MIYASHITA N, Onozawa M, Matsukawa T, Mori A, et al
Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
Br J Haematol. 2024 Jan 18. doi: 10.1111/bjh.19292.
PubMed

NAVRKALOVA V, Plevova K, Radova L, Porc J, et al
Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naive CLL patients.
Br J Haematol. 2024;204:240-249.
PubMed Abstract available

HASSELBALCH HC, Skov V, Kjaer L, Larsen MK, et al
Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
Br J Haematol. 2024;204:16-18.
PubMed Abstract available

GJERTSEN BT
How to discover the exceptional venetoclax responders in AML/MDS?
Br J Haematol. 2024;204:14-15.
PubMed

GESTRICH CK, De Lancy SJ, Kresak A, Meyerson H, et al
IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:229-239.
PubMed Abstract available

BARON F, Nagler A, Galimard JE, Sanz J, et al
Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
Br J Haematol. 2024;204:250-259.
PubMed Abstract available

DE CASTRO FA, Mehdipour P, Chakravarthy A, Ettayebi I, et al
Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
Br J Haematol. 2024;204:206-220.
PubMed Abstract available

NANAA A, He R, Foran JM, Badar T, et al
Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
Br J Haematol. 2024;204:171-176.
PubMed Abstract available

MURPHY EL
HTLV-1 and blood donation.
Br J Haematol. 2024;204:29-30.
PubMed Abstract available

December 2023

HOKLAND P, Fernandez II, Freeman SD, Gjertsen BT, et al
AML in the elderly-A global view.
Br J Haematol. 2023;203:760-773.
PubMed

WU JF, Abid H, Szabo A, Abid MB, et al
Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
Br J Haematol. 2023;203:e117-e120.
PubMed

HERRITY E, Pereira MP, Kim DDH
Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directions.
Br J Haematol. 2023;203:722-735.
PubMed Abstract available

MAHDI D, O'Nions J, Raj K, Baker R, et al
Managing molecular relapse of acute myeloid leukaemia in early pregnancy: Is a watch and wait approach reasonable?
Br J Haematol. 2023;203:e114-e116.
PubMed

QI P, Wang L, Li H, Wu Y, et al
Venetoclax as a cytoreduction therapy for acute promyelocytic leukaemia: A single-centre experience.
Br J Haematol. 2023;203:892-895.
PubMed

PERUSINI MA, Novitzky-Basso I, Atenafu EG, Forrest D, et al
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Br J Haematol. 2023;203:781-791.
PubMed Abstract available

CHIRIAC R, Humbert C, Mejri A, Debliquis A, et al
Charcot-Leyden crystals in acute myeloid leukaemia associated with basophilia.
Br J Haematol. 2023;203:699-700.
PubMed

November 2023

NG JY, Joshi M, Choi P
Frequency and outcomes of obinutuzumab-induced thrombocytopenia.
Br J Haematol. 2023;203:668-672.
PubMed Abstract available

BORLENGHI E, Roccaro AM, Cattaneo C
Rethinking the definition of 'less intensive' for venetoclax-combining regimens in acute myeloid leukaemia patients.
Br J Haematol. 2023;203:504-506.
PubMed Abstract available

REYNOLDS G, Urbancic KF, Fong CY, Trubiano JA, et al
Invasive fungal infection following venetoclax and posaconazole co-administration.
Br J Haematol. 2023;203:593-598.
PubMed Abstract available

OCADLIKOVA D, Lussana F, Fracchiolla N, Bonifacio M, et al
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.
Br J Haematol. 2023;203:637-650.
PubMed Abstract available

BOOTH E, Backx M, Joshi A, Nizami H, et al
Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
Br J Haematol. 2023;203:499-500.
PubMed

DONNETTE M, Hamimed M, Ciccolini J, Sicard G, et al
Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
Br J Haematol. 2023;203:625-636.
PubMed Abstract available

MONTALBAN-BRAVO G, Kanagal-Shamanna R, Li Z, Hammond D, et al
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Br J Haematol. 2023;203:581-592.
PubMed Abstract available

APOLITO V, Arrigo G, Vasseur L, Olivi M, et al
Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax.
Br J Haematol. 2023;203:e98-e101.
PubMed

October 2023

MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
PubMed Abstract available

PAN X, Chang Y, Ruan G, Wei F, et al
Prognostic impact of FLT3-ITD mutation on NPM1(+) acute myeloid leukaemia patients and related molecular mechanisms.
Br J Haematol. 2023;203:212-223.
PubMed Abstract available

MAHDI D, Spiers J, Rampotas A, Polverelli N, et al
Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
Br J Haematol. 2023;203:169-181.
PubMed Abstract available

SEVERIN F, Mouawad N, Ruggeri E, Visentin A, et al
Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness.
Br J Haematol. 2023;203:224-236.
PubMed Abstract available

TRAVAGLINI S, Gurnari C, Antonelli S, Marchesi F, et al
Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept.
Br J Haematol. 2023;203:327-330.
PubMed

EADIE LN, Rehn JA, Schutz CE, Heatley SL, et al
Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling.
Br J Haematol. 2023;203:282-287.
PubMed Abstract available

September 2023

RHODES J
FISH-ing for answers: Can genomic arrays add to our understanding of disease biology in low-risk chronic lymphocytic leukaemia?
Br J Haematol. 2023;202:922-924.
PubMed Abstract available

RADICH JP
The (near) miracle of therapy in chronic myeloid leukaemia.
Br J Haematol. 2023;202:919-921.
PubMed

PATNANA PK, Liu L, Frank D, Nimmagadda SC, et al
Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells.
Br J Haematol. 2023;202:1033-1048.
PubMed Abstract available

HUA L, Yang N, Li Y, Huang K, et al
Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway.
Br J Haematol. 2023;202:971-984.
PubMed Abstract available

LI H, Yuan L, Wang P, Sheng Y, et al
Clonal architecture and single-cell transcriptome landscape in Richter's syndrome.
Br J Haematol. 2023;202:1055-1060.
PubMed

RIGOLIN GM, Traversa A, Caputo V, Del Giudice I, et al
Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients.
Br J Haematol. 2023;202:953-959.
PubMed Abstract available

DE JOHN KO, De Quintal H, Mathibe MD, Albertus N, et al
A rare case of acute megakaryoblastic leukaemia with constitutional ring chromosome 21.
Br J Haematol. 2023;202:912.
PubMed

SHAH NP, Garcia-Gutierrez V, Jimenez-Velasco A, Larson SM, et al
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Br J Haematol. 2023;202:942-952.
PubMed Abstract available

BRECCIA M, Saglio G
Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?
Br J Haematol. 2023;202:1087-1088.
PubMed Abstract available

HADDAD FG, Kourie HR, Saleh K
Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2023;202:1084-1086.
PubMed Abstract available

IRANI YD, Hughes A, Kok CH, Clarson J, et al
Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
Br J Haematol. 2023;202:1127-1136.
PubMed Abstract available

FENG H, Fu Y, Cui Z, Zhou M, et al
Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
Br J Haematol. 2023;202:1178-1191.
PubMed Abstract available

PESCHKE JC, Bergmann R, Mehnert M, Gonzalez Soto KE, et al
FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
Br J Haematol. 2023;202:1137-1150.
PubMed Abstract available

PASTORE F, Gittinger H, Raab S, Tschuri S, et al
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
Br J Haematol. 2023;202:1165-1177.
PubMed Abstract available

XIE M, Lu Y, Ouyang G, Li X, et al
Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
Br J Haematol. 2023;202:1119-1126.
PubMed Abstract available

MATSUMOTO K, Kakazu N, Imataki O, Kondo A, et al
Hairy cell leukaemia with an IGH-BRAF fusion gene.
Br J Haematol. 2023;202:e67-e70.
PubMed

BELHADJ M, Burroni B, Kosmider O, Willems L, et al
Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study.
Br J Haematol. 2023;202:e50-e53.
PubMed

August 2023

LAHERA A, Vela-Martin L, Lopez-Nieva P, Salgado RN, et al
Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL.
Br J Haematol. 2023;202:693-698.
PubMed

GE SS, Qiu QC, Dai HP, Shen XD, et al
Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.
Br J Haematol. 2023;202:539-549.
PubMed Abstract available

MA Z, Ye W, Wang J, Huang X, et al
Glutamate dehydrogenase 1: A novel metabolic target in inhibiting acute myeloid leukaemia progression.
Br J Haematol. 2023;202:566-577.
PubMed Abstract available

ZHOU L, Fu W, Wu S, Xu K, et al
Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.
Br J Haematol. 2023;202:517-524.
PubMed Abstract available

NI SC, Lin CC
Pseudothrombocytosis in Acute Myeloid Leukaemia.
Br J Haematol. 2023;202:456.
PubMed

MILADINOVIC M, Klusmann JH
Influenza A (H1N1) virus induced long-term remission in a refractory acute myeloid leukaemia.
Br J Haematol. 2023;202:713-714.
PubMed Abstract available

HUO WX, Wen Q, Zhang XH, Xu LP, et al
Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia.
Br J Haematol. 2023;202:856-865.
PubMed Abstract available

NG LIET HING M, Ryland GL, Nguyen T, Tiong IS, et al
Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
Br J Haematol. 2023;202:893-896.
PubMed

YOU L, Liu Y, Chen N, Zhu L, et al
Influenza A (H1N1) virus induced long-term remission in a refractory acute myeloid leukaemia.
Br J Haematol. 2023;202:745-748.
PubMed Abstract available

RIVA G, Luppi M, Tagliafico E
From gating to computational flow cytometry: Exploiting artificial intelligence for MRD diagnostics.
Br J Haematol. 2023;202:715-717.
PubMed Abstract available

NGUYEN PC, Nguyen V, Baldwin K, Kankanige Y, et al
Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.
Br J Haematol. 2023;202:760-770.
PubMed Abstract available

KUSUDA M, Nakasone H, Yoshimura K, Okada Y, et al
Gene expression and TCR amino acid sequences selected by HLA-A02:01-restricted CTLs specific to HTLV-1 in ATL patients.
Br J Haematol. 2023;202:578-588.
PubMed Abstract available

LOKE J, Upasani V, Gaskell C, Fox S, et al
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
Br J Haematol. 2023;202:498-503.
PubMed Abstract available

SARTOR C, Brunetti L, Audisio E, Cignetti A, et al
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
Br J Haematol. 2023;202:599-607.
PubMed Abstract available

BORRILL R, Poulton K, Kusyk L, Routledge A, et al
Granulocyte transfusion during cord blood transplant for relapsed, refractory AML is associated with massive CD8(+) T-cell expansion, significant cytokine release syndrome and induction of disease remission.
Br J Haematol. 2023;202:589-598.
PubMed Abstract available

July 2023

KASSEM AM, Keinath MC, Adler JA, Gadde R, et al
ZBTB16::RARA variant acute promyelocytic leukemia (vAPL) treated with gemtuzumab ozogamicin (GO) with unique pathology and genetic findings.
Br J Haematol. 2023 Jul 26. doi: 10.1111/bjh.18950.
PubMed

FALINI B, Cardinali V, Brunetti L, Martelli MP, et al
NPM1-mutated AML with starry sky pattern.
Br J Haematol. 2023;202:8.
PubMed

HUO L, Zhang Z, Zhou H, Xie J, et al
Causative germline variant p.Y259C of DDX41 recurrently identified in acute lymphoblastic leukaemia.
Br J Haematol. 2023;202:199-203.
PubMed

DOAN A, Huang HKT, Hadar AJ, Malvar J, et al
Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.
Br J Haematol. 2023;202:e3-e6.
PubMed

ZHU X, Jiang Q, Lu J, Sun Y, et al
COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China.
Br J Haematol. 2023;202:31-39.
PubMed Abstract available

ZHANG X, Wang Z, Sun J, Liu L, et al
New insights into the clinical characteristics of SETD2-mutated acute myeloid leukaemia.
Br J Haematol. 2023;202:111-115.
PubMed Abstract available

ERKELAND SJ
Computational analysis of a microRNA signature for poor prognosis suggests a microRNA-controlled stemness pathway in paediatric acute leukaemia.
Br J Haematol. 2023;202:11-12.
PubMed Abstract available

FIGUEROA-MORA R, Rampotas A, Halperin D, Worth T, et al
Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.
Br J Haematol. 2023;202:48-53.
PubMed Abstract available

ESPERANZA-CEBOLLADA E, Gomez-Gonzalez S, Perez-Jaume S, Vega-Garcia N, et al
A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia.
Br J Haematol. 2023;202:96-110.
PubMed Abstract available

JO T, Arai Y, Oshima S, Kondo T, et al
Prognostic impact of complex and/or monosomal karyotypes in post-transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach.
Br J Haematol. 2023;202:356-368.
PubMed Abstract available

SYSTCHENKO T, Chomel JC, Gallego-Hernanz P, Moya N, et al
Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
Br J Haematol. 2023;202:284-288.
PubMed Abstract available

STRULLU M, Fenneteau O, Lainey E
Cannibalism in an ETV6::RUNX1 paediatric B acute lymphoblastic leukaemia.
Br J Haematol. 2023;202:211.
PubMed

LI T, Zhang Y, Wang K, Zhou H, et al
Leukaemic blasts in a urine specimen in acute myeloid leukaemia with CEBPA mutation.
Br J Haematol. 2023;202:212.
PubMed

LV M, Liu L, He Y, Yang D, et al
Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease.
Br J Haematol. 2023;202:369-378.
PubMed Abstract available

OFVERHOLM I, Rezayee F, Heyman M, Harila A, et al
The prognostic impact of IKZF1 deletions and UKALL genetic classifiers in paediatric B-cell precursor acute lymphoblastic leukaemia treated according to NOPHO 2008 protocols.
Br J Haematol. 2023;202:384-392.
PubMed Abstract available

WANG W, Li X, Qin X, Miao Y, et al
Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
Br J Haematol. 2023;202:328-343.
PubMed Abstract available

GURNEY M, Chekkaf I, Baranwal A, Basmaci R, et al
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
Br J Haematol. 2023;202:279-283.
PubMed Abstract available

June 2023

MUNTANOLA A, Villalobos MT, Gonzalez-Villambrosia S, Rodriguez-Salazar MJ, et al
Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
Br J Haematol. 2023 Jun 30. doi: 10.1111/bjh.18912.
PubMed Abstract available

TURNER R, Quach H, Horvath N, Kerridge I, et al
Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.
Br J Haematol. 2023 Jun 18. doi: 10.1111/bjh.18914.
PubMed Abstract available

LIU Y, Zhu L, Lv Z, Mao L, et al
Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.
Br J Haematol. 2023;201:995-999.
PubMed

XIE X, Zhang W, Zhou X, Ye Z, et al
Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells.
Br J Haematol. 2023;201:940-953.
PubMed Abstract available

VAINER N, Aarup K, Andersen MA, Wind-Hansen L, et al
Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia.
Br J Haematol. 2023;201:874-886.
PubMed Abstract available

RIEU JB, Canali A, Thene E, Tavitian S, et al
Acute promyelocytic leukaemia associated with atypical basophilia.
Br J Haematol. 2023;201:1017.
PubMed

YOKOYAMA S, Onozawa M, Yoshida S, Miyashita N, et al
Subclinical minute FLT3-ITD clone can be detected in clinically FLT3-ITD-negative acute myeloid leukaemia at diagnosis.
Br J Haematol. 2023;201:1144-1152.
PubMed Abstract available

SIMOES C, Villar S, Ariceta B, Garces JJ, et al
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Br J Haematol. 2023;201:1239-1244.
PubMed

BRONSTEIN Y, Levi S, Herishanu Y
Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge.
Br J Haematol. 2023;201:1125-1128.
PubMed Abstract available

DULUCQ S, Rigal-Huguet F, Nicolini FE, Cony-Makhoul P, et al
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
Br J Haematol. 2023;201:1116-1124.
PubMed Abstract available

MENEZES DL, See WL, Risueno A, Tsai KT, et al
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Br J Haematol. 2023;201:1129-1143.
PubMed Abstract available

NAGLER A, Labopin M, Dholaria B, Blaise D, et al
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
Br J Haematol. 2023;201:1169-1178.
PubMed Abstract available

ISHIDA H, Imamura T, Tatebe Y, Ishihara T, et al
Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukaemia receiving the Japan Association of Childhood Leukaemia Study ALL-02 protocol.
Br J Haematol. 2023;201:1200-1208.
PubMed Abstract available

May 2023

PUCKRIN R, Owen C, Stewart D, Peters A, et al
Real-world management of small lymphocytic lymphoma as chronic lymphocytic leukaemia versus an indolent non-Hodgkin lymphoma.
Br J Haematol. 2023 May 25. doi: 10.1111/bjh.18879.
PubMed

SAVOY L, Long N, Lee H, Chen R, et al
CDK12/13 dual inhibitors are potential therapeutics for acute myeloid leukemia.
Br J Haematol. 2023 May 14. doi: 10.1111/bjh.18843.
PubMed

JEDIDI I, Krichen I, Chaari M, Louati N, et al
Auer-rod like inclusions in mature neutrophils of an early T cell precursor lymphoblastic leukaemia patient after SARS-CoV-2 infection.
Br J Haematol. 2023;201:378.
PubMed

LUNDIN-STROM KB, Biloglav A, Castor A, Olsson-Arvidsson L, et al
Acquired uniparental isodisomies involving chromosome 12 in paediatric B-cell precursor acute lymphoblastic leukaemia: Associations with chromosome 21 gains and SH2B3 mutations.
Br J Haematol. 2023;201:585-588.
PubMed

WANG H, Yao Y, Mao L, Lou Y, et al
Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis.
Br J Haematol. 2023;201:568-572.
PubMed

MAURO FR, Visentin A, Giannarelli D, Molinari MC, et al
Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents.
Br J Haematol. 2023;201:564-567.
PubMed

JING CB, Prutsch N, He S, Zimmerman MW, et al
Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors.
Br J Haematol. 2023;201:489-501.
PubMed Abstract available

CARRILLO-TORNEL S, Chen-Liang TH, Zurdo M, Puiggros A, et al
NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition.
Br J Haematol. 2023;201:470-479.
PubMed Abstract available

TIACCI E, Mancini A, Marchetti M, D'Elia GM, et al
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia.
Br J Haematol. 2023;201:411-416.
PubMed Abstract available

JONART LM, Ostergaard J, Brooks A, Fitzpatrick G, et al
CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
Br J Haematol. 2023;201:459-469.
PubMed Abstract available

POPOV A, Tsaur G, Verzhbitskaya T, Riger T, et al
Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
Br J Haematol. 2023;201:510-519.
PubMed Abstract available

COLLIGNON C, Domenech C, Ducassou S, Pluchart C, et al
Temporary contraindication to chemotherapy due to toxicity: blinatumomab's effectiveness in paediatric patients with B-acute lymphoblastic leukaemia.
Br J Haematol. 2023;201:e42-e45.
PubMed

CHEN R, Atenafu EG, Seki J, Liu X, et al
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
Br J Haematol. 2023;201:645-652.
PubMed Abstract available

LAHERA A, Lopez-Nieva P, Alarcon H, Marin-Rubio JL, et al
SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.
Br J Haematol. 2023;201:718-724.
PubMed Abstract available

HAMA A, Taga T, Tomizawa D, Muramatsu H, et al
Haematopoietic cell transplantation for children with acute megakaryoblastic leukaemia without Down syndrome.
Br J Haematol. 2023;201:747-756.
PubMed Abstract available

KARLSSON L, Cheuk D, De Moerloose B, Hasle H, et al
Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia.
Br J Haematol. 2023;201:757-765.
PubMed Abstract available

April 2023

CASTAGNA L, Patti K, Mule A
Don't forget cord blood in non-remission acute myeloid leukaemia!
Br J Haematol. 2023;201:11-12.
PubMed Abstract available

ZHENG Y, Weng X, Hu D, He J, et al
Identification of a signature based on non-apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia.
Br J Haematol. 2023;201:95-105.
PubMed Abstract available

SORCINI D, De Falco F, Gargaro M, Bozza S, et al
Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia.
Br J Haematol. 2023;201:45-57.
PubMed Abstract available

MATSUDA K, Konuma T, Fuse K, Masuko M, et al
Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: A nationwide retrospective study.
Br J Haematol. 2023;201:106-113.
PubMed Abstract available

DEL GIUDICE I, Cappelli LV, Delgado J, Niemann CU, et al
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.
Br J Haematol. 2023;201:353-356.
PubMed

WANG YH, Yao CY, Lin CC, Gurashi K, et al
A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia.
Br J Haematol. 2023;201:302-307.
PubMed Abstract available

MA H, Wang S, O'Brien S, Kern M, et al
How we approach the perioperative management of patients with chronic lymphocytic leukaemia receiving continuous cancer-directed therapies.
Br J Haematol. 2023;201:215-221.
PubMed Abstract available

SALOMAO N, Maslah N, Giulianelli A, Drevon L, et al
Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia.
Br J Haematol. 2023;201:234-248.
PubMed Abstract available

SINGH C, Yanamandra U, Karunakaran P, Jindal N, et al
Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study.
Br J Haematol. 2023;201:249-255.
PubMed Abstract available

March 2023

SPACEK M, Smolej L, Simkovic M, Nekvindova L, et al
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
Br J Haematol. 2023 Mar 27. doi: 10.1111/bjh.18736.
PubMed Abstract available

SHEN K, Yang C
Occult optic nerve neurolymphomatosis of T-lymphoblastic lymphoma detected by PET/MRI.
Br J Haematol. 2023 Mar 27. doi: 10.1111/bjh.18725.
PubMed

ROUZAUD C, Vercellino L, De Kerviler E, Raffoux E, et al
Prognostic value of PET/CT and CT in T-cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients.
Br J Haematol. 2023 Mar 8. doi: 10.1111/bjh.18707.
PubMed

EL HUSSEIN S, Wang W
Plasmacytoid dendritic cells in the setting of myeloid neoplasms: Diagnostic guide to challenging pathologic presentations.
Br J Haematol. 2023;200:545-555.
PubMed Abstract available

FRISCH A, Rowe JM, Ofran Y
The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia.
Br J Haematol. 2023;200:556-562.
PubMed Abstract available

MATSUDA K, Konuma T, Yanada M
Cord blood versus haploidentical transplantations for non-remission acute myeloid leukaemia: Authors' reply.
Br J Haematol. 2023;200:678-679.
PubMed

SCARADAVOU A, Boelens JJ
Lower probability of relapse after myeloablative cord blood transplantation for patients with refractory AML.
Br J Haematol. 2023;200:676-677.
PubMed

MUSSAI F, De Santo C, Cheng P, Thomas IF, et al
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
Br J Haematol. 2023;200:573-578.
PubMed Abstract available

CHOI Y, Choi EJ, Park HS, Lee JH, et al
A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors-A single-centre, prospective, explorative study.
Br J Haematol. 2023;200:608-621.
PubMed Abstract available

AGUILAR NAVARRO AG, Tikhonova AN
Treatment response in acute myeloid leukaemia-Clues in the biopsy core.
Br J Haematol. 2023;200:691-693.
PubMed Abstract available

TREABA DO, Bonal DM, Chorzalska A, Castillo-Martin M, et al
Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles.
Br J Haematol. 2023;200:740-754.
PubMed Abstract available

February 2023

MESZAROS N, Lind K, Sehlke R, Vilagos B, et al
Influence of cryopreservation on drug responses and gene expression of AML cells: Implications for the use of biobanked tissues.
Br J Haematol. 2023;200:e32-e36.
PubMed

MANGUM DS, Bishop JD, Zhou Y, Cheng C, et al
Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis.
Br J Haematol. 2023;200:338-343.
PubMed Abstract available

CHATTERJEE G, Patkar N
United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward.
Br J Haematol. 2023;200:277-279.
PubMed Abstract available

BARNES EJ, Eide CA, Kaempf A, Bottomly D, et al
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.
Br J Haematol. 2023;200:323-328.
PubMed Abstract available

IKOMA-COLTURATO MRV, Bertolucci CM, Conti-Spilari JE, Oliveira E, et al
Multicentric standardization of minimal/measurable residual disease in B-cell precursor acute lymphoblastic leukaemia using next-generation flow cytometry in a low/middle-level income country.
Br J Haematol. 2023;200:381-384.
PubMed

KULIS M, Martin-Subero JI
Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications.
Br J Haematol. 2023;200:280-290.
PubMed Abstract available

GOURSAUD L, Berthon C, Quesnel B
Successful bridging to cell therapy for relapsed/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG-asparaginase.
Br J Haematol. 2023;200:e37-e39.
PubMed

RAKOTOARIVELO ZH, Lefebvre T, Lamarque M, Harzallah I, et al
Bundles of Auer rods in mature neutrophils in an acute myeloid leukaemia patient with inv(16)(p13.1q22) CBFB-MYH 11.
Br J Haematol. 2023;200:398.
PubMed

TIAN C, Chen Z, Wang L, Si J, et al
Over expression of ubiquitin-conjugating enzyme E2O in bone marrow mesenchymal stromal cells partially attenuates acute myeloid leukaemia progression.
Br J Haematol. 2023;200:476-488.
PubMed Abstract available

HUANG T, Xu L, Zhang X, Chang Y, et al
Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia.
Br J Haematol. 2023;200:494-505.
PubMed Abstract available

MADRY K, Lis K, Fenaux P, Bowen D, et al
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Br J Haematol. 2023;200:451-461.
PubMed Abstract available

DARGENIO M, Bonifacio M, Chiaretti S, Vitale A, et al
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.
Br J Haematol. 2023;200:440-450.
PubMed Abstract available

GJAERDE LK, Jakobsen LH, Juhl-Christensen C, Olesen G, et al
Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population-based cohort study.
Br J Haematol. 2023;200:e40-e43.
PubMed

January 2023

WILSON J
Pseudo-faggot cells in splenic marginal zone lymphoma.
Br J Haematol. 2023 Jan 6. doi: 10.1111/bjh.18621.
PubMed

OLOFSEN PA, Bosch DA, de Looper HWJ, van Strien PMH, et al
Truncated CSF3 receptors induce pro-inflammatory responses in severe congenital neutropenia.
Br J Haematol. 2023;200:79-86.
PubMed Abstract available

ZHANG T, Liu X, Fei H, Zhang L, et al
Improved myeloablative conditioning regimen for allogeneic stem cell transplantation in adult patients with chronic myelomonocytic leukaemia.
Br J Haematol. 2023;200:256-260.
PubMed

PAUL SR, Rosing DR, Haigney MC, Peer CJ, et al
Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia.
Br J Haematol. 2023;200:261-263.
PubMed

WIERNIK PH
Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
Br J Haematol. 2023;200:126-127.
PubMed Abstract available

GURNARI C, Pagliuca S
Digging into the HLA pockets: A new association with acute leukaemias.
Br J Haematol. 2023;200:123-125.
PubMed Abstract available

MEHTA P, Telford N, Wragg C, Dillon R, et al
Recommendations for laboratory testing of UK patients with acute myeloid leukaemia.
Br J Haematol. 2023;200:150-159.
PubMed

BOUKOUACI W, Rivera-Franco MM, Volt F, Wu CL, et al
Comparative analysis of the variability of the human leukocyte antigen peptide-binding pockets in patients with acute leukaemia.
Br J Haematol. 2023;200:197-209.
PubMed Abstract available

PEREIRA-MARTINS DA, Coelho-Silva JL, Weinhauser I, Franca-Neto PL, et al
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia.
Br J Haematol. 2023;200:170-174.
PubMed Abstract available

ROY L, Chomel JC, Guilhot J, Guerci-Bresler A, et al
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Br J Haematol. 2023;200:175-186.
PubMed Abstract available

December 2022

LI H, Xiang X, Ding H, Yu J, et al
Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.
Br J Haematol. 2022;199:768-771.
PubMed

CANALI A, Rieu JB
Morphological characterization of acute myeloid leukaemia with t(11;17)(q23;q21)/ZBTB16::RARA fusion.
Br J Haematol. 2022;199:638.
PubMed

WEI S, Gu R, Song Y, Yan Z, et al
Early-salvage therapy with venetoclax-based regimens for induction failure and poor early response acute lymphoblastic leukaemia: A retrospective case series of 13 patients.
Br J Haematol. 2022;199:772-776.
PubMed

ATKINS O, Mirvis E, Maynard S, Katsomitrou V, et al
Acute myeloid leukaemia presenting with Sweet syndrome.
Br J Haematol. 2022;199:637.
PubMed

MUNIR T, Emmerson J, Hockaday A, Oughton JB, et al
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
Br J Haematol. 2022;199:707-719.
PubMed Abstract available

COPLAND M
Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
Br J Haematol. 2022;199:665-678.
PubMed Abstract available

November 2022

DONG Q, Wang Y, Xiu Y, Sakr H, et al
Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma.
Br J Haematol. 2022 Nov 14. doi: 10.1111/bjh.18565.
PubMed

RIO-MACHIN A
ATM serine/threonine kinase germline mutations in chronic lymphocytic leukaemia come in different flavours.
Br J Haematol. 2022;199:307-309.
PubMed

PETRACKOVA A, Savara J, Turcsanyi P, Gajdos P, et al
Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
Br J Haematol. 2022;199:371-381.
PubMed Abstract available

LI T, Wu P, Wang A, Chen M, et al
A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10 to acute megakaryoblastic leukaemia.
Br J Haematol. 2022;199:305.
PubMed

FORDHAM NJ, Bartram J, Ghorashian S, O'Connor D, et al
What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis?
Br J Haematol. 2022;199:447-451.
PubMed

SHANMUGANATHAN N, Hughes TP
Asciminib for chronic myeloid leukaemia: Next questions.
Br J Haematol. 2022;199:322-331.
PubMed Abstract available

WAN Y, Zhang H, Zhang L, Cai J, et al
Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia.
Br J Haematol. 2022;199:587-596.
PubMed Abstract available

WANG Y, Chen S, Chi P, Nie R, et al
Survival prediction optimization of acute myeloid leukaemia based on T-cell function-related genes and plasma proteins.
Br J Haematol. 2022;199:572-586.
PubMed Abstract available

KRISTENSEN DT, Nielsen LB, Jakobsen LHK, Kristensen TC, et al
Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study.
Br J Haematol. 2022;199:539-548.
PubMed Abstract available

ZHAO C, Wang S, Wang K
Mutual exclusivity between the fusion gene CBFB::MYH11 and somatic mitochondrial mutations in acute myeloid leukaemia.
Br J Haematol. 2022;199:e25-e29.
PubMed

QIANG X, Chen S, Chen X
Peritoneal infiltration by leukaemic promyelocytes in acute promyelocytic leukaemia at initial diagnosis.
Br J Haematol. 2022;199:475.
PubMed

KOTMAYER L, Romero-Moya D, Marin-Bejar O, Kozyra E, et al
GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.
Br J Haematol. 2022;199:482-495.
PubMed Abstract available

October 2022

ANDERSSON NG, Rathe M, Molle I, Jarvis KB, et al
A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management.
Br J Haematol. 2022;199:117-121.
PubMed Abstract available

BARRETT J
Screening for mercaptopurine intolerance in ALL - target the genes or their product?
Br J Haematol. 2022;199:173-174.
PubMed Abstract available

DENNIS M, Copland M, Kaur H, Kell J, et al
Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.
Br J Haematol. 2022;199:205-221.
PubMed

TANAKA Y, Urayama KY, Mori M, Arakawa Y, et al
Prominence of NUDT15 genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia.
Br J Haematol. 2022;199:260-269.
PubMed Abstract available

YOSHIDA M, Brown SA, Moriyama T, Nishii R, et al
Low NUDT15 expression levels due to biallelic NUDT15 variants and 6-mercaptopurine intolerance.
Br J Haematol. 2022;199:270-276.
PubMed Abstract available

DILLON J, Mykytiv V, Keenan C, Mullaney B, et al
Management of a patient with acute myeloid leukaemia with a diagnosis of type 2 von Willebrand disease and a novel variant within the von Willebrand factor (VWF) gene.
Br J Haematol. 2022;199:e5-e7.
PubMed

ALSOUQI A, Rothenberger SD, Boyiadzis M, Lontos K, et al
Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database.
Br J Haematol. 2022;199:256-259.
PubMed Abstract available

HAMPEL PJ, Rabe KG, Call TG, Ding W, et al
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
Br J Haematol. 2022;199:239-244.
PubMed Abstract available

September 2022

GREINER J, Goetz M, Schuler PJ, Bulach C, et al
Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.
Br J Haematol. 2022;198:866-874.
PubMed Abstract available

YEOH DK, Blyth CC, Kotecha RS
Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease.
Br J Haematol. 2022;198:887-892.
PubMed Abstract available

ALBERTSEN BK, Lynggaard LS, Schmiegelow K
Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
Br J Haematol. 2022;198:e84-e85.
PubMed

BRECCIA M, Olimpieri PP, Celant S, Olimpieri O, et al
Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA).
Br J Haematol. 2022;198:965-973.
PubMed Abstract available

LI J, Liu L, Zhang R, Wan Y, et al
Development and validation of a prognostic scoring model to risk stratify childhood acute myeloid leukaemia.
Br J Haematol. 2022;198:1041-1050.
PubMed Abstract available

VAN DER SLUIS IM, Bertrand Y, Baruchel A, Pieters R, et al
Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?
Br J Haematol. 2022;198:e82-e83.
PubMed

MOGENSEN N, Saaranen E, Olsson E, Klug Albertsen B, et al
Quality of life in mothers and fathers of children treated for acute lymphoblastic leukaemia in Sweden, Finland and Denmark.
Br J Haematol. 2022;198:1032-1040.
PubMed Abstract available

MOPPETT J
Metabolomics: A biomarker to improve the assessment of central nervous system positive acute lymphoblastic leukaemia?
Br J Haematol. 2022;198:939-940.
PubMed

TAYLOR GP, Cook LB
A new paradigm for the management of ATL.
Br J Haematol. 2022;198:941-942.
PubMed

FAVINI C, Talotta D, Almasri M, Andorno A, et al
Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.
Br J Haematol. 2022;198:1016-1022.
PubMed Abstract available

HARRINGTON P, Dillon R, Radia D, McLornan D, et al
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.
Br J Haematol. 2022;198:1011-1015.
PubMed Abstract available

SONG Z, Tang G, Zhuang C, Wang Y, et al
Metabolomic profiling of cerebrospinal fluid reveals an early diagnostic model for central nervous system involvement in acute lymphoblastic leukaemia.
Br J Haematol. 2022;198:994-1010.
PubMed Abstract available

August 2022

NAKHODA S, Vistarop A, Wang YL
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Br J Haematol. 2022 Aug 27. doi: 10.1111/bjh.18418.
PubMed Abstract available

ISIDORI A, Loscocco F, Visani G, Paolasini S, et al
Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
Br J Haematol. 2022 Aug 24. doi: 10.1111/bjh.18426.
PubMed Abstract available

IMBERY JF, Heinzelbecker J, Jebsen JK, McGowan M, et al
T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation.
Br J Haematol. 2022;198:556-573.
PubMed Abstract available

WANG X, Tang G, Hu Z, Fang H, et al
Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival.
Br J Haematol. 2022;198:604-608.
PubMed

SANCHEZ-VIZCAINO F, Tamayo C, Ramos F, Lainez-Gonzalez D, et al
Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population-based study.
Br J Haematol. 2022;198:545-555.
PubMed Abstract available

LU L, Kok CH, Dang P, Branford S, et al
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission.
Br J Haematol. 2022;198:600-603.
PubMed

PODVIN B, Guermouche H, Fournier E, Berthon C, et al
Acute myeloid leukaemia with double minute chromosomes encompassing the 8q24 region.
Br J Haematol. 2022;198:413.
PubMed

CHAN WY, Zhu C, Sanchez E, Gupta R, et al
Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies.
Br J Haematol. 2022;198:478-481.
PubMed

HERAUDET L, Galtier J, Favre S, Peyraud F, et al
VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
Br J Haematol. 2022;198:523-527.
PubMed Abstract available

JAMY O, Lin K, Worth S, Bachiashvili K, et al
Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
Br J Haematol. 2022;198:e35-e37.
PubMed

ALHAJ ISSA Z, Altwijri A, Alfayez M
Cerebral nocardiosis in ibrutinib-treated chronic lymphocytic leukaemia.
Br J Haematol. 2022;198:414.
PubMed

ADES L, Duployez N, Guerci-Bresler A, Laribi K, et al
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Br J Haematol. 2022;198:535-544.
PubMed Abstract available

RUSSELL NH, Hills RK, Kjeldsen L, Clark RE, et al
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Br J Haematol. 2022;198:528-534.
PubMed Abstract available

VALTIS YK, Place AE, Silverman LB, Vrooman LM, et al
Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia.
Br J Haematol. 2022;198:421-430.
PubMed Abstract available

VOLPE VO, Al Ali N, Chan O, Padron E, et al
Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
Br J Haematol. 2022;198:713-720.
PubMed Abstract available

MULLIGAN SP, Opat S, Marlton P, Kuss B, et al
Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia.
Br J Haematol. 2022;198:790-793.
PubMed

GENTHON A, Dragoi D, Memoli M, Hirsch P, et al
Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia.
Br J Haematol. 2022;198:780-784.
PubMed

LAURA CS, Ana FM, Ines LH
Pure erythroid leukaemia mimicking metastatic carcinoma.
Br J Haematol. 2022;198:617.
PubMed

July 2022

STRATI P, Coleman M, Champion R, Ma S, et al
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18368.
PubMed Abstract available

ROLDAN GALIACHO V, Zaldumbide Duenas L, Lobo Olmedo A, Alonso Varela M, et al
Intracytoplasmic crystalline inclusions in peripheral blood lymphocytes in small lymphocytic lymphoma.
Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18380.
PubMed

MEYER LK, Delgado-Martin C, Sharp PP, Huang BJ, et al
Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2022;198:137-141.
PubMed Abstract available

GHANDILI S, Kluger MA, Leitner T, Grahammer F, et al
Donor-transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation.
Br J Haematol. 2022;198:199-202.
PubMed

KRIEL M, Opie J, Louw V, Musekwa E, et al
Clover leaf nuclear morphology in chronic lymphocytic leukaemia with typical immunophenotype and absence of trisomy 12.
Br J Haematol. 2022;198:8.
PubMed

PIMENTEL-VILLAR MA, Morales-Camacho RM, Vargas MT, Jimenez-Jambrina M, et al
Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1.
Br J Haematol. 2022;198:7.
PubMed

CLAXTON DF
Beware clonal haematopoiesis following chronic lymphocytic leukaemia treatment.
Br J Haematol. 2022;198:9-10.
PubMed

SIDHU J, Masurekar AN, Gogoi MP, Fong C, et al
Activity and toxicity of intramuscular 1000 iu/m(2) polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.
Br J Haematol. 2022;198:142-150.
PubMed Abstract available

WANG J, Jiang H, Jing Y, Su L, et al
Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Br J Haematol. 2022;198:e3-e8.
PubMed

VOSO MT, Pandzic T, Falconi G, Dencic-Fekete M, et al
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.
Br J Haematol. 2022;198:103-113.
PubMed Abstract available

DE PROPRIS MS, Musiu P, Intoppa S, Nardacci MG, et al
Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall.
Br J Haematol. 2022;198:e28-e31.
PubMed

STENGEL S, Petrie KR, Sbirkov Y, Stanko C, et al
Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
Br J Haematol. 2022;198:338-348.
PubMed Abstract available

DHUNPUTH C, Strullu M, Petit A, Merched M, et al
Single-dose (4.5 mg/m(2) ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia.
Br J Haematol. 2022;198:373-381.
PubMed Abstract available

SHIVAROV V, Grigorova D
Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia.
Br J Haematol. 2022;198:e23-e25.
PubMed

GUO JJ, Cao L, Zhu HY, Miao Y, et al
T-cell large granular lymphocytic leukaemia with atypical immunophenotypes: A single-centre retrospective analysis of 17 cases.
Br J Haematol. 2022;198:e18-e22.
PubMed

June 2022

KATAYAMA S, Hiraishi T, Ota M
Skin manifestations of intravascular adult T-cell leukaemia/lymphoma.
Br J Haematol. 2022 Jun 27. doi: 10.1111/bjh.18318.
PubMed

BRIVIO E, Cossio A, Borra D, Silvestri D, et al
Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort.
Br J Haematol. 2022;197:602-608.
PubMed Abstract available

WALEWSKA R, Parry-Jones N, Eyre TA, Follows G, et al
Guideline for the treatment of chronic lymphocytic leukaemia.
Br J Haematol. 2022;197:544-557.
PubMed

MOIA R, Gaidano G
Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia.
Br J Haematol. 2022;197:513-514.
PubMed

WANG QQ, Wang HF, Zhao JZ, Naranmandura H, et al
Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
Br J Haematol. 2022;197:e58-e60.
PubMed

MERLI P
Treating second-relapsed/refractory first-relapsed childhood acute myeloid leukaemia: Successful salvage rather than palliation?
Br J Haematol. 2022;197:651-652.
PubMed Abstract available

WANG M, Lin H, Chu X, Wang Z, et al
Identification of a recurrent fusion NUP98-RARG in acute myeloid leukaemia resembling acute promyelocytic leukaemia.
Br J Haematol. 2022;197:e73-e78.
PubMed

LYNGGAARD LS, Vaitkeviciene G, Langenskiold C, Lehmann AK, et al
Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
Br J Haematol. 2022;197:745-754.
PubMed Abstract available

TARIQ H, Barnea Slonim L, Coty Fattal Z, Alikhan MB, et al
Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype.
Br J Haematol. 2022;197:736-744.
PubMed Abstract available

MORI A, Onozawa M, Tsukamoto S, Ishio T, et al
Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
Br J Haematol. 2022;197:691-696.
PubMed Abstract available

WHITE T, Kaspers G, Abrahamsson J, Arad-Cohen N, et al
Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO-DB SHIP consortium.
Br J Haematol. 2022;197:755-765.
PubMed Abstract available

May 2022

SHICHIJO T, Nosaka K, Tatetsu H, Higuchi Y, et al
Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma.
Br J Haematol. 2022 May 24. doi: 10.1111/bjh.18281.
PubMed Abstract available

ZHU K, Jamroz A, Huang S, Villa D, et al
Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
Br J Haematol. 2022 May 14. doi: 10.1111/bjh.18241.
PubMed Abstract available

JOBSON D, McCormack CJ, Mar V, Tam C, et al
Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study.
Br J Haematol. 2022;197:320-325.
PubMed Abstract available

TAYLOR T, Byrne J, Errico G, Clark D, et al
Very late extramedullary relapse of acute myeloid leukaemia as prostatic myeloid sarcoma occurring 24 years post-allograft.
Br J Haematol. 2022;197:243.
PubMed

OLIVEIRA AF, Tansini A, Toledo T, Balceiro R, et al

Br J Haematol. 2022;197:339-348.
PubMed Abstract available

UJJANI C, Shadman M, Lynch RC, Tu B, et al
The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
Br J Haematol. 2022;197:306-309.
PubMed Abstract available

CARTWRIGHT A, Scott S, Francis S, Whitby L, et al
Assessing the impact of the 2017 European LeukemiaNet recommendations on FLT3 allelic ratio calculation and reporting in acute myeloid leukaemia.
Br J Haematol. 2022;197:e35-e37.
PubMed

PETERSEN MA, Rosenberg CA, Brondum RF, Aggerholm A, et al
Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups.
Br J Haematol. 2022;197:452-466.
PubMed Abstract available

WEI H, Zhou C, Liu B, Lin D, et al
The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
Br J Haematol. 2022;197:442-451.
PubMed Abstract available

LEW TE, Anderson MA
Health-related quality of life for patients with chronic lymphocytic leukaemia - A critical outcome measure in the era of highly effective therapies.
Br J Haematol. 2022;197:394-396.
PubMed

OERLEMANS S, Efficace F, Kieffer JM, Kyriakou C, et al
International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia.
Br J Haematol. 2022;197:431-441.
PubMed Abstract available

JACOBY E, Bielorai B, Hutt D, Itzhaki O, et al
Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
Br J Haematol. 2022;197:475-481.
PubMed Abstract available

ALTER BP, Giri N, McReynolds LJ, Altintas B, et al
Fanconi anaemia: A syndrome with distinct subgroups.
Br J Haematol. 2022;197:467-474.
PubMed Abstract available

YU Q, Yu D, Chen X
Cup-shaped nuclei in acute promyelocytic leukaemia.
Br J Haematol. 2022;197:389.
PubMed

April 2022

SUN C
COVID-19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion.
Br J Haematol. 2022;197:11-12.
PubMed

SHEN Y, Freeman JA, Holland J, Solterbeck A, et al
COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
Br J Haematol. 2022;197:41-51.
PubMed Abstract available

CLAUDIANI S, Apperley JF, Parker EL, Marchesin F, et al
Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
Br J Haematol. 2022;197:e1-e4.
PubMed

ON S, Rath CG, Lan M, Wu B, et al
Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
Br J Haematol. 2022;197:63-70.
PubMed Abstract available

GADI D, Griffith A, Wang Z, Tyekucheva S, et al
Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
Br J Haematol. 2022;197:207-211.
PubMed Abstract available

RECKZEH K, Estruch M, Ali M, Sogaard Helbo A, et al
TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event.
Br J Haematol. 2022;197:201-206.
PubMed

BRANFORD S
BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
Br J Haematol. 2022;197:9-10.
PubMed

DOMINY KM, Claudiani S, O'Hare M, Szydlo R, et al
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Br J Haematol. 2022;197:52-62.
PubMed Abstract available

VERBEEK MWC, Buracchi C, Laqua A, Nierkens S, et al
Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
Br J Haematol. 2022;197:76-81.
PubMed Abstract available

HILLS RK
Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?
Br J Haematol. 2022;197:e26-e27.
PubMed

YEUNG DTO, Osborn MP, White DL
B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification.
Br J Haematol. 2022;197:13-27.
PubMed Abstract available

TONG WH
Does anticoagulation prophylaxis reduce the rate of venous thromboembolism in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy?
Br J Haematol. 2022;197:e24-e25.
PubMed

JENSEN K, Oskarsson T, Lahteenmaki P, Flaegstad T, et al
Doing less, accomplishing more for childhood ALL: response.
Br J Haematol. 2022;197:120.
PubMed

March 2022

CULL G, Burger JA, Opat S, Gottlieb D, et al
Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Br J Haematol. 2022;196:1209-1218.
PubMed Abstract available

MORIYA K, Imamura T, Katayama S, Kaino A, et al
The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Munster (BFM)95-based protocol.
Br J Haematol. 2022;196:1257-1261.
PubMed Abstract available

MAAS CCHM, van Klaveren D, Ector GICG, Posthuma EFM, et al
The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.
Br J Haematol. 2022;196:1219-1224.
PubMed Abstract available

BARZILAI-BIRENBOIM S, Elitzur S, Nirel R, Ehrenberg M, et al
Elevated intraocular pressure in children with acute lymphoblastic leukaemia: A prospective study.
Br J Haematol. 2022;196:1248-1256.
PubMed Abstract available

DILLON R, Hills RK, Burnett AK, Russell NH, et al
Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials.
Br J Haematol. 2022;196:e50-e52.
PubMed

WALDRON C, O'Brien D, Brophy S, Perera K, et al
Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning.
Br J Haematol. 2022;196:e47-e49.
PubMed

EGNELL C, Heyman M, Jonsson OG, Raja RA, et al
Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia.
Br J Haematol. 2022;196:1239-1247.
PubMed Abstract available

GALLIPOLI P, Clark RE, Byrne J, Apperley JF, et al
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
Br J Haematol. 2022;196:e55-e57.
PubMed

COATS T, Bean D, Basset A, Sirkis T, et al
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
Br J Haematol. 2022;196:1337-1343.
PubMed Abstract available

SALHOTRA A, Tsai NC, Zhang J, Ngo D, et al
Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
Br J Haematol. 2022;196:e71-e74.
PubMed

RUSSELL N, Hills R, Kjeldsen L, Dennis M, et al
Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
Br J Haematol. 2022;196:1344-1347.
PubMed Abstract available

MCCLURE BJ, Pal M, Heatley SL, Rehn J, et al
Two novel cases of NUTM1-rearranged B-cell acute lymphoblastic leukaemia presenting with high-risk features.
Br J Haematol. 2022;196:1407-1411.
PubMed

LINCH DC, Hills RK, Burnett AK, Russell N, et al
Therapy for isocitrate dehydrogenase 2 (IDH2)(R172) -mutant acute myeloid leukaemia.
Br J Haematol. 2022;196:1348-1352.
PubMed Abstract available

BENDE RJ, Janssen J, van Noesel CJM
Higher-order of chronic lymphocytic leukaemia (CLL) classification: shared antigenic specificities of stereotyped B-cell receptor subsets as defined by the European Research Initiative on CLL consortium.
Br J Haematol. 2022;196:e60-e63.
PubMed

TAWANA K, Brown AL, Churpek JE
Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges.
Br J Haematol. 2022;196:1293-1310.
PubMed Abstract available

February 2022

CLAUDIANI S
Is COVID-19 less severe in CML patients than in those with other haematological cancers?
Br J Haematol. 2022;196:471-472.
PubMed

BRECCIA M, Abruzzese E, Accurso V, Attolico I, et al
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol. 2022;196:559-565.
PubMed Abstract available

SCHENKER C, Hirzel C, Walti LN, Zeerleder SS, et al
Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.
Br J Haematol. 2022;196:e27-e29.
PubMed

BIONDI A, Conter V, Chandy M, Ewald P, et al
Precursor B-cell acute lymphoblastic leukaemia-a global view.
Br J Haematol. 2022;196:530-547.
PubMed Abstract available

SALEK C, Folber F, Fronkova E, Pecherkova P, et al
Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant.
Br J Haematol. 2022;196:706-710.
PubMed Abstract available

DOWNES CEJ, Rehn J, Heatley SL, Yeung D, et al
Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2022;196:700-705.
PubMed Abstract available

SCHWAB CJ, Murdy D, Butler E, Enshaei A, et al
Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification.
Br J Haematol. 2022;196:753-763.
PubMed Abstract available

TANDON S, Visser R, Astwood E, Payne J, et al
Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature.
Br J Haematol. 2022;196:e34-e39.
PubMed

KRIEG S, Seeger H, Hofmann P, Del Prete C, et al
Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia.
Br J Haematol. 2022;196:781-784.
PubMed

VOJDEMAN FJ, Helby J, Pedersen LB, Brieghel C, et al
Chronic lymphocytic leukaemia clones are detectable decades before diagnosis.
Br J Haematol. 2022;196:784-787.
PubMed

HUANG W, Sundquist K, Sundquist J, Ji J, et al
Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
Br J Haematol. 2022;196:690-699.
PubMed Abstract available

RIBERA J, Granada I, Morgades M, Gonzalez T, et al
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
Br J Haematol. 2022;196:670-675.
PubMed Abstract available

BOOTH S, Curley HM, Varnai C, Arnold R, et al
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
Br J Haematol. 2022;196:892-901.
PubMed Abstract available

ALLAN JN, Shanafelt T, Wiestner A, Moreno C, et al
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Br J Haematol. 2022;196:947-953.
PubMed Abstract available

AHMED HMM, Nimmagadda SC, Al-Matary YS, Fiori M, et al
Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells.
Br J Haematol. 2022;196:995-1006.
PubMed Abstract available

SHEN Z, Zhou M, Zhang J, Chen S, et al
Microgranular variant of acute promyelocytic leukaemia with an unusual T/myeloid immunophenotype resembling that of mixed-phenotype acute leukaemia.
Br J Haematol. 2022;196:801.
PubMed

ABDEL RAHMAN ZH, Parrondo RD, Heckman MG, Wieczorek M, et al
Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.
Br J Haematol. 2022;196:963-968.
PubMed Abstract available

EYRE TA, Riches JC, Patten PEM, Walewska R, et al
Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper.
Br J Haematol. 2022;196:864-870.
PubMed

January 2022

TOMOWIAK C, Leblond V, Laribi K, Baron M, et al
Response to vaccination against SARS-CoV-2 in 168 patients with Waldenstrom macroglobulinemia: a French Innovative Leukemia Organization (FILO) study.
Br J Haematol. 2022 Jan 14. doi: 10.1111/bjh.18055.
PubMed

NAVILLE AS, Lazaro E, Boutin J, Prot-Leurent C, et al
Acquired glucose 6-phosphate dehydrogenase (G6PD) deficiency in a patient with Chronic Myelomonocytic Leukemia.
Br J Haematol. 2022 Jan 6. doi: 10.1111/bjh.18037.
PubMed

SAULTIER P, Ninove L, Szepetowski S, Veneziano M, et al
Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.
Br J Haematol. 2022;196:e1-e3.
PubMed

MARCHESI F, Pimpinelli F, Sperandio E, Papa E, et al
The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
Br J Haematol. 2022;196:362-367.
PubMed

GASTINNE T, Le Bourgeois A, Coste-Burel M, Guillaume T, et al
Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
Br J Haematol. 2022;196:360-362.
PubMed

SEVIAR D, Nyunt K, Sayer C, Wright D, et al
Romboutsia-induced bone marrow necrosis at presentation of acute myeloid leukaemia.
Br J Haematol. 2022;196:262.
PubMed

YAO H, Huo L, Ping N, Liu H, et al
Recurrent mutations in multiple components of the SWI/SNF complex in myelodysplastic syndromes and acute myeloid leukaemia.
Br J Haematol. 2022;196:441-444.
PubMed

KIM DDH, Kim TS, Atenafu EG, Novitzky Basso I, et al
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
Br J Haematol. 2022;196:136-145.
PubMed Abstract available

LOKE J, Metzner M, Boucher R, Jackson A, et al
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
Br J Haematol. 2022;196:368-373.
PubMed Abstract available

PODVIN B, Goursaud L, Roynard P, Nibourel O, et al
Chronic myeloid leukaemia presenting with monocytosis.
Br J Haematol. 2022;196:8.
PubMed

NAKAJIMA R, Matsuo T, Sumiyoshi R, Saito S, et al
Extramedullary blast crisis in a chronic myeloid leukaemia patient after achieving a major molecular response with bosutinib.
Br J Haematol. 2022;196:e9-e11.
PubMed

KAYSER S, Levis MJ
Updates on targeted therapies for acute myeloid leukaemia.
Br J Haematol. 2022;196:316-328.
PubMed Abstract available

MIKHAILOVA E, Roumiantseva J, Illarionova O, Lagoyko S, et al
Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
Br J Haematol. 2022;196:e6-e9.
PubMed

SHANMUGANATHAN N, Branford S
Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing.
Br J Haematol. 2022;196:19-30.
PubMed Abstract available

December 2021

FOX TA, Kirkwood AA, Enfield L, O'Reilly M, et al
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
Br J Haematol. 2021;195:706-709.
PubMed

KIM HS, Lee JW, Kang D, Yu H, et al
Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
Br J Haematol. 2021;195:748-756.
PubMed Abstract available

MINGUELA A, Salido EJ, Soto-Ramirez MF, Olga MA, et al
Low-affinity immunoglobulin gamma Fc region receptor III-B (FcgammaRIIIB, CD16B) deficiency in patients with blood and immune system disorders.
Br J Haematol. 2021;195:743-747.
PubMed Abstract available

SILLA L, Valim V, Pezzi A, da Silva M, et al
Adoptive immunotherapy with double-bright (CD56(bright) /CD16(bright) ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study.
Br J Haematol. 2021;195:710-721.
PubMed Abstract available

TANG FF, Lu SY, Zhao XS, Qin YZ, et al
PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort stud
Br J Haematol. 2021;195:722-730.
PubMed Abstract available

November 2021

FOX CP, Ahearne MJ, Pettengell R, Dearden C, et al
Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
Br J Haematol. 2021 Nov 22. doi: 10.1111/bjh.17951.
PubMed

BENDA M, Mutschlechner B, Ulmer H, Grabher C, et al
Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
Br J Haematol. 2021;195:523-531.
PubMed Abstract available

SHIMONI A, Robin M, Iacobelli S, Beelen D, et al
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Br J Haematol. 2021;195:417-428.
PubMed Abstract available

HWANG J, Singh N, Braniecki M, Gok Yavuz B, et al
Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis.
Br J Haematol. 2021;195:e138-e141.
PubMed

SMYTH L, Blunt DN, Cheung MC
Statins in mature B-cell lymphomas and leukaemias.
Br J Haematol. 2021;195:490-492.
PubMed

SOLANO DE LA ASUNCION C, Terol MJ, Saus A, Olea B, et al
Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
Br J Haematol. 2021;195:637-641.
PubMed

BEGNA KH, Kittur J, Yui J, Gangat N, et al
De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases.
Br J Haematol. 2021;195:413-416.
PubMed Abstract available

ZHONG ZQ, Zhuang HF, Wu SL, Zhang H, et al
Pseudo-Chediak-Higashi inclusions in relapsed acute lymphoblastic leukaemia.
Br J Haematol. 2021;195:300.
PubMed

SKOU AS, Juul-Dam KL, Ommen HB, Hasle H, et al
Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
Br J Haematol. 2021;195:310-327.
PubMed Abstract available

October 2021

NOSAKA K, Kusumoto S, Nakano N, Choi I, et al
Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17895.
PubMed Abstract available

LIU M, Zhao X, Pan W, Qian Z, et al
A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy.
Br J Haematol. 2021;195:e123-e128.
PubMed

BARTRAM J, Balasch-Carulla M, Bhojaraja S, Adams S, et al
Blinatumomab for paediatric mixed phenotype acute leukaemia.
Br J Haematol. 2021;195:289-292.
PubMed

EDWARDS K, Zaitseva K, Sayed U, Volpi EV, et al
Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia.
Br J Haematol. 2021;195:e131-e134.
PubMed

TESTI AM, Mohamed S, Diverio D, Piciocchi A, et al
Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience.
Br J Haematol. 2021;195:278-283.
PubMed

BEZDEKOVA R, Jelinek T, Kralova R, Stork M, et al
Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
Br J Haematol. 2021;195:95-107.
PubMed Abstract available

GOULD C, Lickiss J, Kankanige Y, Yerneni S, et al
Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
Br J Haematol. 2021;195:113-118.
PubMed Abstract available

THASTRUP M, Marquart HV, Levinsen M, Modvig S, et al
Flow cytometric analysis of cerebrospinal fluid improves detection of leukaemic blasts in infants with acute lymphoblastic leukaemia.
Br J Haematol. 2021;195:119-122.
PubMed Abstract available

O'CONNOR D, Loke J, Brown M, Stanworth SJ, et al
Non-pharmacological supportive-care interventions in acute myeloid leukaemia: a review of randomised controlled trials.
Br J Haematol. 2021;195:e97-e113.
PubMed

MAENG CV, Ostgard LSG, Christiansen CF, Liu KD, et al
Changes in intensive care unit admission rates, organ support, and mortality in patients with acute myeloid leukaemia over a 12-year period: a Danish nationwide cohort study.
Br J Haematol. 2021;195:137-140.
PubMed

September 2021

COOK LBM
Adult T-cell leukaemia/lymphoma and the trouble with TP53.
Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17830.
PubMed

CHATTERJEE G, Sriram H, Ghogale S, Deshpande N, et al
Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
Br J Haematol. 2021 Sep 2. doi: 10.1111/bjh.17801.
PubMed Abstract available

CHOWDHURY O, Bruguier H, Mallett G, Sousos N, et al
Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
Br J Haematol. 2021;194:1010-1015.
PubMed

HARRINGTON P, Doores KJ, Radia D, O'Reilly A, et al
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
Br J Haematol. 2021;194:999-1006.
PubMed Abstract available

A special issue on modern genomics in diagnostic haematology.
Br J Haematol. 2021;194:801-802.
PubMed

KUIPER RP, Hoogeveen PG, Bladergroen R, van Dijk F, et al
Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all.
Br J Haematol. 2021;194:888-892.
PubMed Abstract available

KHAN M, Roddy JT, Hernandez JR, Bursch K, et al
Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML.
Br J Haematol. 2021;194:1083-1085.
PubMed

RASCHE A, Mason EF, Strickland SA, Byrne M, et al
Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.
Br J Haematol. 2021;194:927-931.
PubMed

ALCALDE-MELLADO P, Franco-Macias E, Morales-Camacho RM, Caballero-Velazquez T, et al
Auer rod-like inclusions in cerebrospinal fluid in accelerated phase chronic lymphocytic leukaemia.
Br J Haematol. 2021;194:946.
PubMed

August 2021

SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
Br J Haematol. 2021 Aug 17. doi: 10.1111/bjh.17749.
PubMed Abstract available

FANG H, Wang W, El Hussein S, Morita K, et al
B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
Br J Haematol. 2021 Aug 16. doi: 10.1111/bjh.17681.
PubMed Abstract available

HENRY A, Bracquemart C, Naguib D, Chantepie S, et al
Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.
Br J Haematol. 2021 Aug 15. doi: 10.1111/bjh.17761.
PubMed

PATEL PA, Lapp SA, Grubbs G, Edara VV, et al
Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
Br J Haematol. 2021;194:549-553.
PubMed

LUCCHINI G, Furness C, Lawson S, Gibson B, et al
COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
Br J Haematol. 2021;194:e74-e77.
PubMed

YEOH AEJ, Oh BL, Ariffin H
Doing less, accomplishing more for childhood acute lymphoblastic leukaemia (ALL).
Br J Haematol. 2021;194:661-662.
PubMed

NOURA M, Morita K, Kiyose H, Okuno Y, et al
Albendazole induces the terminal differentiation of acute myeloid leukaemia cells to monocytes by stimulating the Kruppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) axis.
Br J Haematol. 2021;194:598-603.
PubMed Abstract available

RAMDENY PS, Mullanfroze K, de Lorenzo P, Grazia Valsecchi M, et al
Infant T-cell acute lymphoblastic leukaemia with t(6;7) (TCRB-MYB) translocation.
Br J Haematol. 2021;194:613-616.
PubMed Abstract available

ROMZOVA M, Smitalova D, Hynst J, Tom N, et al
Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
Br J Haematol. 2021;194:604-612.
PubMed Abstract available

MASLAH N, Diawara Y, Sebert M, Giraudier S, et al
In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
Br J Haematol. 2021;194:e77-e79.
PubMed

JENSEN KS, Oskarsson T, Lahteenmaki PM, Flaegstad T, et al
Detection mode of childhood acute lymphoblastic leukaemia relapse and its effect on survival: a Nordic population-based cohort study.
Br J Haematol. 2021;194:734-744.
PubMed Abstract available

CORNEAU A, Parizot C, Cherai M, Todesco E, et al
Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.
Br J Haematol. 2021;194:788-792.
PubMed

ALLSUP D, Howard D, Emmerson J, Hockaday A, et al
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
Br J Haematol. 2021;194:646-650.
PubMed

LOBO-OLMEDO A, Roldan Galiacho V, Arzuaga-Mendez J, Ancin I, et al
Acute megakaryoblastic leukaemia with erythrophagocytosis.
Br J Haematol. 2021;194:658.
PubMed

July 2021

BRANVALL E, Ekberg S, Eloranta S, Wasterlid T, et al
Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
Br J Haematol. 2021 Jul 31. doi: 10.1111/bjh.17733.
PubMed Abstract available

MOIA R, Favini C, Ferri V, Forestieri G, et al
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17718.
PubMed Abstract available

HEHLMANN R
What is the right dosage of dasatinib for treating chronic myeloid leukaemia?
Br J Haematol. 2021;194:234.
PubMed

ROUSSELOT P, Mollica L, Guilhot J, Guerci A, et al
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Br J Haematol. 2021;194:393-402.
PubMed Abstract available

NAKAMURA M, Arai Y, Hirabayashi S, Kondo T, et al
Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.
Br J Haematol. 2021;194:403-413.
PubMed Abstract available

COMONT T, Meunier M, Cherait A, Santana C, et al
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
Br J Haematol. 2021;194:336-343.
PubMed Abstract available

WIERNIK PH, Sun Z, Cripe LD, Rowe JM, et al
Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia.
Br J Haematol. 2021;194:309-318.
PubMed Abstract available

ROEKER LE, Thompson MC, Mato AR
Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice.
Br J Haematol. 2021;194:9-10.
PubMed

MULRONEY CM, Abid MB, Bashey A, Chemaly RF, et al
Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.
Br J Haematol. 2021;194:145-157.
PubMed Abstract available

EYRE TA, Preston G, Kagdi H, Islam A, et al
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
Br J Haematol. 2021;194:69-77.
PubMed Abstract available

SASAKI K, Tsujimoto S, Miyake M, Uchiyama Y, et al
Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
Br J Haematol. 2021;194:414-422.
PubMed Abstract available

SCOTT S, Cartwright A, Francis S, Whitby L, et al
Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
Br J Haematol. 2021;194:53-60.
PubMed Abstract available

RADICH J
Building a better mousetrap for accurate and sensitive polymerase chain reaction.
Br J Haematol. 2021;194:11-13.
PubMed

SASSEN SDT, Mathot RAA, Pieters R, de Haas V, et al
Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response.
Br J Haematol. 2021;194:423-432.
PubMed Abstract available

KOUKOULIAS K, Papadopoulou A, Kouimtzidis A, Papayanni PG, et al
Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine.
Br J Haematol. 2021;194:158-167.
PubMed Abstract available

BODOR C, Kotmayer L, Laszlo T, Takacs F, et al
Screening and monitoring of the BTK(C481S) mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
Br J Haematol. 2021;194:355-364.
PubMed Abstract available

MICHALOWSKI MB, Cecconello DK, Lins MM, Carvalho MDPSS, et al
Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study.
Br J Haematol. 2021;194:168-173.
PubMed Abstract available

ZHAO Y, McCracken J, Rehder C, Wang E, et al
Biclonal evolution of chronic lymphocytic leukaemia.
Br J Haematol. 2021;194:e64-e66.
PubMed

CHERNG HJ, Jammal N, Paul S, Wang X, et al
Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
Br J Haematol. 2021;194:61-68.
PubMed Abstract available

DENNIS M, Burnett A, Hills R, Thomas I, et al
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Br J Haematol. 2021;194:298-308.
PubMed Abstract available

POCOCK R, Farah N, Richardson SE, Mansour MR, et al
Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2021;194:28-43.
PubMed Abstract available

ASSANTO GM, Riemma C, Malaspina F, Perrone S, et al
The current role of interferon in hairy cell leukaemia: clinical and molecular aspects.
Br J Haematol. 2021;194:78-82.
PubMed Abstract available

POPOV A, Fominikh V, Mikhailova E, Shelikhova L, et al
Blinatumomab following haematopoietic stem cell transplantation - a novel approach for the treatment of acute lymphoblastic leukaemia in infants.
Br J Haematol. 2021;194:174-178.
PubMed Abstract available

KOLLA BC, Halim NAA, Cao Q, Sachs Z, et al
High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
Br J Haematol. 2021;194:140-144.
PubMed Abstract available

HSU H, Roncolato F, Lee SH
Lysosomal acid lipase deficiency diagnosed in a patient presenting with acute myeloid leukaemia.
Br J Haematol. 2021;194:228.
PubMed

SHACKLETON L, McCarthy J, Mykytiv V
Extramedullary pericardial haematopoiesis as a presenting feature of chronic myeloid leukaemia.
Br J Haematol. 2021;194:7.
PubMed

June 2021

OSTERGAARD J, Jonart LM, Ebadi M, Koppenhafer SL, et al
Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17610.
PubMed

KARANTANOS T, Gondek LP, Varadhan R, Moliterno AR, et al
Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Br J Haematol. 2021;193:1142-1150.
PubMed Abstract available

XU R, Huang X, Li C, Deng C, et al
Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/beta-catenin signalling by parallel RNA sequencing and dysfunctional phenotypes.
Br J Haematol. 2021;193:928-940.
PubMed Abstract available

MOSKORZ W, Cosmovici C, Jager PS, Cadeddu RP, et al
Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies.
Br J Haematol. 2021;193:941-945.
PubMed Abstract available

CAO H, Neerincx A, de Bono B, Lakner U, et al
Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells.
Br J Haematol. 2021;193:946-950.
PubMed Abstract available

DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
Br J Haematol. 2021;193:1060-1075.
PubMed Abstract available

NISHIMURA A, Naruto T, Miyamoto S, Grigg A, et al
Genomics analysis of leukaemia predisposition in X-linked agammaglobulinaemia.
Br J Haematol. 2021;193:1277-1281.
PubMed

VAN DE GEER A, Zandstra J, Tanck MWT, Nur E, et al
Biomarkers to predict infection and infection-related complications during chemotherapy-induced neutropenia in acute myeloid leukaemia: a pilot study.
Br J Haematol. 2021;193:1008-1012.
PubMed

SHAH MV, Saliba RM, Varma A, Ciurea SO, et al
Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
Br J Haematol. 2021;193:1004-1008.
PubMed

FLYGT H, Sandin F, Dahlen T, Dremaine A, et al
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Br J Haematol. 2021;193:915-921.
PubMed Abstract available

WANG H, Zhou Y, Huang X, Zhang Y, et al
Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2021;193:1096-1104.
PubMed Abstract available

CREUZET E, Nourrisson C, Chaleteix C, Poirier P, et al
Cerebral aspergillosis in a patient on ibrutinib therapy.
Br J Haematol. 2021;193:1025.
PubMed

DANDER E, Fallati A, Gulic T, Pagni F, et al
Monocyte-macrophage polarization and recruitment pathways in the tumour microenvironment of B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2021;193:1157-1171.
PubMed Abstract available

TSAUR G, Popov A, Riger T, Kustanovich A, et al
Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
Br J Haematol. 2021;193:1151-1156.
PubMed Abstract available

BRIVIO E, Chantrain CF, Gruber TA, Thano A, et al
Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
Br J Haematol. 2021;193:1172-1177.
PubMed Abstract available

BRAS AE, Osmani Z, de Haas V, Jongen-Lavrencic M, et al
Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia.
Br J Haematol. 2021;193:922-927.
PubMed Abstract available

May 2021

CHANDER G, Nikolousis E, Kanellopoulos A
Human papilloma virus (HPV)-associated lesions in a post-bone marrow transplant patient responding to HPV vaccination.
Br J Haematol. 2021 May 2. doi: 10.1111/bjh.17514.
PubMed

ROSS DM
How much imatinib is enough?
Br J Haematol. 2021;193:699-700.
PubMed

KIM DDH, Novitzky-Basso I, Kim TS, Atenafu EG, et al
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
Br J Haematol. 2021;193:779-791.
PubMed Abstract available

KHARFAN-DABAJA MA, Labopin M, Brissot E, Kroger N, et al
Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
Br J Haematol. 2021;193:592-601.
PubMed Abstract available

AOKI K, Kurashige M, Ichii M, Higaki K, et al
Identification of CXCL12-abundant reticular cells in human adult bone marrow.
Br J Haematol. 2021;193:659-668.
PubMed Abstract available

MIKHAILOVA E, Semchenkova A, Illarionova O, Kashpor S, et al
Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Br J Haematol. 2021;193:602-612.
PubMed Abstract available

SEMBILL S, Gohring G, Schirmer E, Lutterloh F, et al
Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics.
Br J Haematol. 2021;193:613-618.
PubMed Abstract available

DE MIGUEL SANCHEZ C, Robles de Castro D, Pison Herrero C, Perez Persona E, et al
Primary plasma cell leukaemia presenting with flower-shaped nuclei.
Br J Haematol. 2021;193:689.
PubMed

CHEN D, Chen W
Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
Br J Haematol. 2021;193:691.
PubMed

NOY-LOTAN S, Krasnov T, Dgany O, Jeison M, et al
Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
Br J Haematol. 2021;193:570-580.
PubMed Abstract available

HJORT JAKOBSEN L, Stidsholt Roug A, Kiesbye Ovlisen A, Werenberg Marcher C, et al
Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study.
Br J Haematol. 2021;193:482-487.
PubMed Abstract available

SMOLEJ L
Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
Br J Haematol. 2021;193:723-726.
PubMed Abstract available

April 2021

DO C, Best OG, Thurgood L, Hotinski A, et al
Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
PubMed Abstract available

ZHENG J, Wu S, Hu Y, Gao L, et al
Management of ETV6-ABL1-positive childhood acute lymphoblastic leukaemia: report of two cases, a literature review and a call for action.
Br J Haematol. 2021;193:197-200.
PubMed

GANESAN P, Jain H, Bagal B, Subramanian PG, et al
Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC).
Br J Haematol. 2021;193:e1-e4.
PubMed

FITTER S, Bradey AL, Kok CH, Noll JE, et al
CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2021;193:171-175.
PubMed Abstract available

TROUSSARD X, Grever MR
The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant.
Br J Haematol. 2021;193:11-14.
PubMed

GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
Br J Haematol. 2021;193:72-82.
PubMed Abstract available

SMOLEJ L, Turcsanyi P, Kubova Z, Zuchnicka J, et al
External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.
Br J Haematol. 2021;193:133-137.
PubMed Abstract available

DANILOV AV, Persky DO
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Br J Haematol. 2021;193:15-25.
PubMed Abstract available

RASTOGI N, Baker S, Man S, Uger RA, et al
Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
Br J Haematol. 2021;193:155-159.
PubMed Abstract available

GURNARI C, Breccia M, Di Giuliano F, Scalzulli E, et al
Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters.
Br J Haematol. 2021;193:129-132.
PubMed Abstract available

STILGENBAUER S, Bosch F, Ilhan O, Kisro J, et al
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Br J Haematol. 2021;193:325-338.
PubMed Abstract available

DA CUNHA-BANG C, Rostgaard K, Andersen MA, Rotbain EC, et al
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
Br J Haematol. 2021;193:339-345.
PubMed Abstract available

SOVERINI S, Martelli M, Bavaro L, De Benedittis C, et al
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Br J Haematol. 2021;193:271-279.
PubMed Abstract available

CLAUDIANI S, Apperley JF, Szydlo R, Khan A, et al
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
Br J Haematol. 2021;193:346-355.
PubMed Abstract available

DILLON R, Potter N, Freeman S, Russell N, et al
How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).
Br J Haematol. 2021;193:231-244.
PubMed Abstract available

March 2021

HASSERJIAN RP
Flow cytometry reveals the nuances of clonal haematopoiesis.
Br J Haematol. 2021;192:949-950.
PubMed

BECKER MW, Angelucci E
A large co-operative biological and clinical study to better understand and improve treatment of the rare t(8;16)(p11;p13) acute myeloid leukaemia.
Br J Haematol. 2021;192:800-802.
PubMed

LOGHAVI S, DiNardo CD, Furudate K, Takahashi K, et al
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
Br J Haematol. 2021;192:1054-1063.
PubMed Abstract available

SCHLIEMANN C, Kessler T, Berdel AF, Hemmerle T, et al
Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
Br J Haematol. 2021;192:e148-e151.
PubMed

FERRARI A, Ghelli Luserna Di Rora A, Domizio C, Papayannidis C, et al
Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
Br J Haematol. 2021;192:e139-e144.
PubMed

RIGOLIN GM, Saccenti E, Melandri A, Cavallari M, et al
In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome.
Br J Haematol. 2021;192:1068-1072.
PubMed Abstract available

TIONG IS, Dillon R, Ivey A, Teh TC, et al
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Br J Haematol. 2021;192:1026-1030.
PubMed Abstract available

QU S, Li B, Qin T, Xu Z, et al
Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
Br J Haematol. 2021;192:1006-1010.
PubMed Abstract available

LUNDIN-STROM KB, Biloglav A, Lazarevic V, Behrendtz M, et al
Parental origin of monosomy 7 in acute leukaemia.
Br J Haematol. 2021;192:e132-e135.
PubMed

KAYSER S, Hills RK, Langova R, Kramer M, et al
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
Br J Haematol. 2021;192:832-842.
PubMed Abstract available

February 2021

SMOLEJ L, Brychtova Y, Cmunt E, Doubek M, et al
Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL St
Br J Haematol. 2021 Feb 22. doi: 10.1111/bjh.17373.
PubMed Abstract available

WOUTERS Y, Nevejan L, Louwagie A, Devos H, et al
Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
Br J Haematol. 2021;192:e112-e115.
PubMed

WANG J
Leukaemia blues - an unusual presentation of leukaemia cutis.
Br J Haematol. 2021;192:676.
PubMed

GORDON MJ, Huang J, Chan RJ, Bhargava P, et al
Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
Br J Haematol. 2021;192:720-728.
PubMed Abstract available

EGHOLM GJ, Andersen MA, Andersen CL, Frederiksen H, et al
Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival.
Br J Haematol. 2021;192:e81-e84.
PubMed

HOTINSKI AK, Best OG, Thurgood LA, Lower KM, et al
A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
Br J Haematol. 2021;192:e77-e81.
PubMed

ALI AM, Cooper J, Walker A, Jones D, et al
Adult-onset acute myeloid leukaemia in a patient with germline mutation of CBL.
Br J Haematol. 2021;192:665-667.
PubMed

BRAUNSTEIN Z, Mishra A, Staub A, Freud AG, et al
Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.
Br J Haematol. 2021;192:484-493.
PubMed Abstract available

FLOETH M, Elges S, Gerss J, Schwoppe C, et al
Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
Br J Haematol. 2021;192:494-503.
PubMed Abstract available

MORENO BERGGREN D, Kjellander M, Backlund E, Engvall M, et al
Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
Br J Haematol. 2021;192:474-483.
PubMed Abstract available

DIAMANTI P, Ede BC, Dace PE, Barendt WJ, et al
Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
Br J Haematol. 2021;192:577-588.
PubMed Abstract available

January 2021

BRECCIA M
Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
Br J Haematol. 2021;192:237-238.
PubMed

ROSS DM, Hughes TP
Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge.
Br J Haematol. 2021;192:24-27.
PubMed Abstract available

KARAGIANNIS P, Alsdorf W, Tallarek AC, Blohm ME, et al
Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
Br J Haematol. 2021;192:e60-e63.
PubMed

FOUZIA NA, Sharma V, Ganesan S, Palani HK, et al
Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
Br J Haematol. 2021;192:292-299.
PubMed Abstract available

JIN W, Chen L, Liu Y, Chen Q, et al
A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia.
Br J Haematol. 2021;192:e32-e36.
PubMed

OTTAVIANO G, Baird S, Bonney D, Connor P, et al
The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults.
Br J Haematol. 2021;192:e42-e44.
PubMed

CAVALLINI C, Galasso M, Pozza ED, Chignola R, et al
Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
Br J Haematol. 2021;192:333-342.
PubMed Abstract available

GALE RP, Saglio G
Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?
Br J Haematol. 2021;192:22-23.
PubMed

MATSUO H, Wakita T, Hiramatsu H, Ohmori K, et al
Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.
Br J Haematol. 2021;192:e7-e11.
PubMed

MASON CC, Fiol CR, Baker MJ, Nadal-Melsio E, et al
Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
Br J Haematol. 2021;192:137-145.
PubMed Abstract available

FRISANCO OLIVEIRA A, Tansini A, Toledo TR, Balceiro R, et al
Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
Br J Haematol. 2021;192:129-136.
PubMed Abstract available

RADICH J
Molecular testing of chronic myeloid leukaemia in low resource areas.
Br J Haematol. 2021;192:28-32.
PubMed Abstract available

DUAN W, Liu X, Jia J, Wang J, et al
The loss or absence of minimal residual disease of <0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
Br J Haematol. 2021;192:265-271.
PubMed Abstract available

MILOJKOVIC D, Cross NCP, Ali S, Byrne J, et al
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
Br J Haematol. 2021;192:62-74.
PubMed Abstract available

December 2020

NAKAHATA S, Morishita K
Commentary on: clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
Br J Haematol. 2020 Dec 14. doi: 10.1111/bjh.17214.
PubMed

November 2020

ZHANG X, Suo S, Wang J, Jin J, et al
IDH1(R132S) -mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC.
Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17199.
PubMed

SAKAMOTO Y, Ishida T, Masaki A, Takeshita M, et al
Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
Br J Haematol. 2020 Nov 18. doi: 10.1111/bjh.17211.
PubMed Abstract available

October 2020

HERISHANU Y, Levi S, Kamdjou T, Bornstein Y, et al
Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17105.
PubMed

April 2020

AOKI T, Takahashi H, Tanaka S, Shiba N, et al
Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
Br J Haematol. 2020 Apr 26. doi: 10.1111/bjh.16656.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.